The selective p19 interleukin (IL)-23 blocker guselkumab (Tremfya) was safe and reduced disease activity in adults with moderate to severe Crohn's disease who had an inadequate response to prior ...

In a previous video, investigator Jessica Allegretti, MD, of the Crohn's and Colitis Center at Brigham and Women's Hospital in Boston, discussed the results from the QUASAR phase III induction study ...

“Treatment with guselkumab led to significant improvement in the chronic symptoms of ulcerative colitis with the capability of normalising the appearance of the intestinal lining,” said Laurent Peyrin ...

Please provide your email address to receive an email when new articles are posted on . Guselkumab dosing every 16 weeks was noninferior to dosing every 8 weeks for maintaining psoriasis disease ...

Significantly, from the pooled GALAXI 2 and 3 study results, guselkumab also demonstrated greater efficacy compared to ustekinumab in endoscopic response and endoscopic remission e at Week 48. 3 ...

At week 140, 80.8% of those administered guselkumab achieved clinical remission.

Guselkumab achieved clear or almost clear skin in 74.2% of patients with moderate plaque psoriasis, compared to 12.4% on placebo. The VISIBLE study showed rapid and significant clearance of scalp ...

Please provide your email address to receive an email when new articles are posted on . CHARLOTTE, N.C. — Guselkumab in combination with golimumab induced greater rates of clinical remission compared ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) for the treatment of Crohn’s disease and ulcerative colitis (UC). Already used for plaque psoriasis and ...

Guselkumab demonstrated strong efficacy in treating moderate to severe scalp psoriasis, especially in individuals with skin of color, achieving nearly 70% complete scalp clearance by week 48. The ...

CHARLOTTE, NC — People with moderate-to-severe ulcerative colitis benefit from stronger treatment from the start — a combination of monoclonal antibodies — compared with induction with either agent ...